Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo

A JemalR SiegelJ XuE WardCancer statistics, 2010CA Cancer J Clin60277300201010.3322/caac.20073

L HouwenState of the art: lung cancer in ChinaAnn Thorac Cardiovasc Surg9147148200312882182

DM vanHE Karim-KosS SieslingProgress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 yearsJ Thorac Oncol7291298201222157366

MA BareschinoC SchettinoA RossiTreatment of advanced non small cell lung cancerJ Thorac Dis3122133201122263075

BS NairV BhanderiSH JafriCurrent and emerging pharmacotherapies for the treatment of relapsed small cell lung cancerClin Med Insights Oncol5223234201121836818

A AshkenaziRC PaiS FongSafety and antitumor activity of recombinant soluble Apo2 ligandJ Clin Invest104155162199910.1172/JCI692610411544

JC SoriaE SmitD KhayatPhase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancerJ Clin Oncol2815271533201010.1200/JCO.2009.25.484720159815

G PanRK OAM ChinnaiyanThe receptor for the cytotoxic ligand TRAILScience276111113199710.1126/science.276.5309.1119082980

H WalczakMA Degli-EspostiRS JohnsonTRAIL-R2: a novel apoptosis-mediating receptor for TRAILEMBO J1653865397199710.1093/emboj/16.17.53869311998

SA MarstersJP SheridanRM PittiA novel receptor for Apo2L/TRAIL contains a truncated death domainCurr Biol710031006199710.1016/S0960-9822(06)00422-29382840

JG EmeryP McDonnellMB BurkeOsteoprotegerin is a receptor for the cytotoxic ligand TRAILJ Biol Chem2731436314367199810.1074/jbc.273.23.143639603945

Y ZhangJH WangQ LuYJ WangBag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancerOncol Rep1109113201121971866

G KroemerThe proto-oncogene Bcl-2 and its role in regulating apoptosisNat Med3614620199710.1038/nm0697-6149176486

TS GriffithDH LynchTRAIL: a molecule with multiple receptors and control mechanismsCurr Opin Immunol10559563199810.1016/S0952-7915(98)80224-09794836

LL CarrJH FiniganJA KernEvaluation and treatment of patients with non-small cell lung cancerMed Clin North Am9510411054201110.1016/j.mcna.2011.08.00122032426

BD DalyRJ CerfolioMJ KrasnaRole of surgery following induction therapy for stage III non-small cell lung cancerSurg Oncol Clin N Am20721732201110.1016/j.soc.2011.07.00621986268

MH ColemanR BuenoRole of adjuvant chemotherapy in NSCLC (stages I to III)Surg Oncol Clin N Am20757767201110.1016/j.soc.2011.07.01121986270

A AshkenaziTargeting death and decoy receptors of the tumour-necrosis factor superfamilyNat Rev Cancer2420430200210.1038/nrc82112189384

EE McGrathThe tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: still following the right TRAIL?J Thorac Oncol6983987201110.1097/JTO.0b013e318217b6c821623278

AJ BridgeS PebernardA DucrauxAL NicoulazR IggoInduction of an interferon response by RNAi vectors in mammalian cellsNat Genet34263264200310.1038/ng117312796781

JE CaretteRM OvermeerFH SchagenConditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cellsCancer Res6426632667200410.1158/0008-5472.CAN-03-353015087375

SH KaufmannWC EarnshawInduction of apoptosis by cancer chemotherapyExp Cell Res2564249200010.1006/excr.2000.483810739650

A GrossJM McDonnellSJ KorsmeyerBcl-2 family members and the mitochondria in apoptosisGenes Dev1318991911199910.1101/gad.13.15.189910444588

B JansenU Zangemeister-WittkeAntisense therapy for cancer - the time of truthLancet Oncol3672683200210.1016/S1470-2045(02)00903-812424069

S CoryJM AdamsThe Bcl-2 family: regulators of the cellular life-or-death switchNat Rev Cancer2647656200210.1038/nrc88312209154